Plain-English translation of NCT07235059 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is one of the first times this treatment has been tested in people.
This trial is testing a new medication called to see if it is safe and well-tolerated in people's bodies, and whether it might help treat chronic kidney disease. The study starts by giving healthy volunteers small doses to make sure the medication is safe, then gradually tests it in people who actually have kidney disease. Researchers will carefully monitor participants to understand how the medication works and what side effects, if any, occur.
Chronic kidney disease is a serious condition that can progress and lead to kidney failure. Researchers are developing this medication as a potential new treatment option to help slow or manage kidney disease, offering hope for patients who need additional therapy options beyond current standard care.
You likely qualify if…
You likely don't qualify if…
The study has three phases. In the first phase, healthy volunteers receive single doses of the medication starting at very low levels and gradually increasing to see how the body tolerates it. In the second phase, people with kidney disease receive single doses at carefully chosen levels. In the third phase, people with kidney disease receive multiple doses over time. Throughout the study, participants will visit the clinic multiple times for blood tests, heart monitoring, and other safety checks to ensure the medication is working safely.
AI-generated summary from trial data · Aug 30, 2026 · Not medical advice
United States
Germany